Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444049 · ClinicalTrials.gov registry record · NA
NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)
A NA study of Cardiovascular Diseases and Cardiac Arrest, sponsored by neurescue.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05444049: Completed NA study of Cardiovascular Diseases and Cardiac Arrest, sponsored by neurescue.
NCT05444049 is a NA study of Cardiovascular Diseases and Cardiac Arrest that has completed, run by neurescue. The registered enrollment target is 6 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05444049, a NA study of Cardiovascular Diseases and Cardiac Arrest, has completed, sponsored by neurescue.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body. The objective of this study is to investigate the feasibility of the NEURESCUE device as an adjunct to Advanced Cardiac Life Support (ACLS) in adults with cardiac arrest.
Conditions Studied
Interventions
- DEVICE NEURESCUE device
Study Locations (1)
California
- Long Beach Medical Center - Long Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
What the finished NCT05444049 record still lists
NCT05444049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which NEURESCUE device is the first listed.
NCT05444049 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05444049 about?
NCT05444049 is a clinical study titled "NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)". The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in t...
What is the current status of trial NCT05444049?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2022-12-08. Estimated completion is 2024-09-30.
What conditions does trial NCT05444049 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Cardiac Arrest, Cardiopulmonary Arrest.
What interventions are being tested in trial NCT05444049?
The interventions under investigation include: NEURESCUE device (DEVICE).
Who is sponsoring clinical trial NCT05444049?
This trial is sponsored by neurescue, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05444049 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05444049's enrollment target sits among peer trials
6 297th of 300 higher than 4 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI